Spyre Therapeutics
SYRE
59 hedge funds and large institutions have $140M invested in Spyre Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 13 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.83% less ownership
Funds ownership: 67.19% → 66.36% (-0.83%)
8% less funds holding
Funds holding: 64 → 59 (-5)
10% less capital invested
Capital invested by funds: $155M → $140M (-$15.2M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.94M |
| 2 |
O
OrbiMed
New York
|
+$2.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.48M |
| 4 |
BlackRock
New York
|
+$1.93M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.04M |
| 2 |
SFM
Soros Fund Management
New York
|
-$2.18M |
| 3 |
SI
SCP Investment
Orinda,
California
|
-$1.65M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.39M |
| 5 |
JP Morgan Chase
New York
|
-$694K |
SYRE Hedge Fund Activity: Q3 2018 in Review
59 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2018, worth a combined $140M — down 9.8% from $155M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SYRE and 8 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 23 added.
The largest buyer was Nantahala Capital Management, adding an estimated $2.94M. The largest seller was Millennium Management, exiting entirely with an estimated $5.04M sold.
- 59 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2018, down from 64 in Q2 2018.
- Funds reported $140M of Spyre Therapeutics stock for Q3 2018, down 9.8% quarter-over-quarter.
- 8 funds opened new Spyre Therapeutics positions in Q3 2018 and 13 closed out, a net change of -5 holders.
- The largest Spyre Therapeutics buyer in Q3 2018 was Nantahala Capital Management, an estimated $2.94M added.
- The largest Spyre Therapeutics seller in Q3 2018 was Millennium Management, an estimated $5.04M sold.
Based on aggregated 13F filings for Q3 2018.